Idiopathic short stature (ISS) refers to children with shorten growth of body where the reason behind the physical condition is unknown. The children with height less than 2 standard deviations (SDs) are categorized in this clinical condition. The group of idiopathic short children includes children with delay of growth and puberty, hereditary short stature, children with subtle cartilage and bone dysplasias. There is no precise medical cause for ISS, whereas some reasons include genetic structure and other orthopedic related complications. 
The disease often diagnosed by X-rays of the left wrist or hand along with complete blood count, growth hormone stimulation test, insulin growth factor-1 test and other blood related tests. Though there is ongoing debate about treatment of ISS based on growth hormones but based on the physical and blood test, generally hormonal therapy is recommended by health care professionals In 2003, United States Food and Drug Administration (FDA) approved human growth hormone treatment for children with idiopathic short stature (height below 2.25 SD). According to survey conducted by European Society of Endocrinologist, 94% physicians prefer growth hormone treatment for ISS. 
Children with idiopathic short stature can be found in all parts of the world. According to The Endocrine Society based in United States, It is estimated that approximately 60 – 80% of all children across the globe with short stature fit in the category of ISS and therefore total number of people living with ISS will increase accordingly. The above fact stands for demand of various treatment options for ISS globally. The heavy investment in research and development, suitable reimbursement conditions and growing number of patients living with ISS may drive the growth of the market. On the other hand limited awareness and lack of specific treatment may hinder the growth of the overall market. 
Currently there are many clinical research projects under study that are focused on developing specific treatment for idiopathic short stature. Merck KGaA has “Saizen” in pipeline for treatment of affected children, Pfizer in collaboration with prestigious Rabin Medical Center exploring the use of biochemical markers of growth with growth hormone treatment, Eli Lilly and Company trying to develop monotherapy of somatropin in pubertal children with ISS, Dong-A Pharmaceutical Co., Ltd. is studying the improvement of height of children by growth hormone therapy.
Idiopathic short stature market can be segmented according to different categories such as regional geography, classification of ISS and categories of drugs available for the treatment. Geographically, this market can be segmented in four regions namely North American, Europe, Asia-Pacific and Rest of the World, out of all these segments North America region have highest contribution in terms of value because of high awareness, higher percentage of total income spent on healthcare compared to other economies and appropriate reimbursement circumstances. Followed by this, Europe, Asia-Pacific and Rest of the World respectively could be major segments of the market. The treatment market can also be segmented according to categories such as familial ISS and non-familial ISS. According to treatment options available, the market for ISS can be segmented in Growth hormones, genetic therapy and others.  
Currently many established players in pharmaceuticals market which are either catering or on the way to develop drugs for idiopathic short stature. Out of these companies, JCR Pharmaceuticals Co., Braasch Biotech LLC, Bolder Biotechnology, Inc., Myungmoon pharmaceutical Co. Ltd, Eli Lilly, Pfizer are leading contributors.

This intelligence report by TMR is the outcome of intense study and rigorous assessment of various dynamics shaping the growth of the market. TMR nurtures a close-knit team of analysts, strategists, and industry experts who offer clients tools, methodologies, and frameworks to make smarter decisions. Our objective, insights, and actionable analytics provide CXOs and executives to advance their mission-critical priorities with confidence.

The scrutiny of the various forces impacting the dynamics of the market, and key and associated industries, guides enterprises in understanding various consumer propositions. Our clients leverage these insights and perspectives to enhance customer experience in the fast-paced business environment.

All our insights and perspectives are broadly based on 4 Pillars or Stages: ASBC-S, which offer an elaborate and customizable framework for the success of an organization. The essence and the roles of these in organizational successes are highlighted below:

  • Agenda for CXOs: TMR, through the study, sets the tone for agendas that are pertinent to CEOs, CFOs, CIOs, and other CXO executives of businesses operating in the market. The perspectives help our clients to bridge the gap between agenda and action plan. TMR strives to offer guidance to CXOs to undertake mission-critical activities empowered by various business analysis tools, and boost the performance of the organizations. The perspectives guide you to decide on your own marketing mix that align well with the policies, visions, and mission.
  • Strategic Frameworks: The study offers how organizations are setting both short-term and long-term strategic plans. Our team of experts collaborate and communicate with you to understand these to make your organizations sustainable and resilient during tough times. The insights help them decide sustainable competitive advantage for each business units.
  • Benchmarking for Deciding Target Markets and Brand Positioning: The assessments in the study provides a scrutiny of marketing channels and marketing mix. Our various teams work synergistically with you to help identify your actual and potential direct, indirect, and budget competition areas. Additionally, the study helps you decide most effective budgets for various processes and promotional activities. Furthermore, the study guides you to set benchmarks for integrating people and processes with the 4Ps of marketing. Eventually, this will empower you to find out unique propositioning strategies and niches.
  • Business Composability for Sustainability (C-S): Constant strategy planning for sustainability characterizing our C-S framework in the report has become more relevant than before in the face of disruptions caused by pandemics, recessions, boom and bust cycles, and changing geopolitical scenario. The TMR study offers a high level of customization to help you achieve business composability. Composable enterprises are increasingly gaining the attention of CXOs in order to help them combat market volatility. Our analysts and industry experts help you wade through such uncertainties and guide you to become a smart sustainable business in entirety.

The study presents scrutiny of region-specific consumer and technology trends, including the most recent industry dynamics. These broadly cover but not limited to

  • North America, South America, and the Americas
  • Asia Pacific and Japan
  • Europe
  • Latin America
  • Middle East and Africa

The study offers data-driven insights and guidance of several aspects. Some of the more notable questions are:

  • What are the major recent trends that can influence the product life cycle and the RoI?
  • Which regulatory trends shape corporate-level, business-level, and functional-level strategies?
  • Which micromarketing initiatives of leading players will bring in investments?
  • What can be the best framework and tools for PESTLE analysis?
  • Which regions will witness rise in new opportunities?
  • Which are the game-changing technologies being used to capture new revenue streams in the near future?
  • Which operational and tactical frameworks are being adopted by various players in gaining customer loyalty?
  • What is the current and expected intensity of competition the market in the near future?

Disclaimer: This market research study is an ongoing effort and extreme care has been taken to maintain the highest levels of accuracy at all stages. However, in the light of the rapidly evolving business dynamics, some region-specific or other segment-specific changes may take time to be part of the study.

Enquiry Before Buying

TMR offers Enquiry Before Buying that help clients to get information on their business scenario required where syndicated solutions are not enough.

Enquiry Before Buying

Idiopathic Short Stature Market